Glaxosmithkline Pharmaceuticals

    GLAXO
    Pharma
    ₹2,638.20
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹44,693 Cr

    P/E
    38.98
    Day range
    ₹2,620.20 – ₹2,699.00
    52-week range
    ₹2,088.10 – ₹3,120.70
    Volume
    87,837
    Open
    ₹2,698.80
    Prev close
    ₹2,687.60

    Latest results · Q2 FY27(consolidated)Revenue ₹1,184 Cr+20.8%Profit ₹336 Cr+30.4%Margin 28.4%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 69 / 100

    Factor percentiles

    Value34
    Quality91
    Momentum63
    Low volatility86

    Derived metrics

    Earn. yield
    2.6%
    Graham no.
    ₹405.86
    vs Graham
    -84.6%
    ROE ÷ P/B
    2.0%
    12-1 mom.
    +1.0%
    Return / vol
    0.15
    Magic Formula
    #117
    FCF yield
    1.9%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Glaxosmithkline PharmaceuticalsGLAXO₹44,693 Cr38.9824.0849.1%61.0%34.0%0.02+20.8%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 2d ago

    Headlines about Glaxosmithkline Pharmaceuticals from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    39.4
    Price / Book
    23.77
    ROE (FY26)
    49.1%
    ROCE (latest year)
    61%
    Dividend yield
    2.16%

    Moving averages (NSE)

    20-day
    ₹2,556.76
    Price above
    50-day
    ₹2,674.42
    Price below
    200-day
    ₹2,528.99
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +5.5%
    Profit 3Y CAGR
    +19.2%
    Revenue YoY (Sep 2026)
    +20.8%
    Profit YoY (Sep 2026)
    +30.7%
    Operating margin
    34.0%
    Net margin
    28.4%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr500 Cr1K Cr1.5K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr3K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%25%50%75%100%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 11 Sept 2018: earlier bars are per pre-bonus share.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹20₹40₹60

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales8059308151,0119499748059801,0419959381,184
    YoY Sales growth——————-1-3————
    Expenses587673584689658641554644670644643782
    Operating Profit218257231322292333251336371351296402
    OPM %27%28%28%32%31%34%31%34%36%35%31%34%
    Other Income-1353236393541443650364473
    Interest010001011110
    Depreciation171816171915161720131615
    Profit before tax65271249344308359279354400373322459
    Tax %30%28%27%27%25%27%27%27%26%26%26%27%
    Net Profit46194182252230263205257296278237336
    EPS in Rs₹2.70₹11.48₹10.76₹14.91₹13.57₹15.52₹12.10₹15.20₹17.45₹16.40₹14.00₹19.83

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days26

    -1 days since Mar 2021

    Inventory Days124

    -35 days since Mar 2021

    Days Payable154

    +19 days since Mar 2021

    Cash Conversion Cycle-4

    -54 days since Mar 2021

    Working Capital Days-91

    -52 days since Mar 2021

    Strengths, risks & growth

    GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

    Strengths

    • Company is almost debt free.
    • Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
    • Company has been maintaining a healthy dividend payout of 94.6%

    Risks

    • Stock is trading at 23.8 times its book value
    • The company has delivered a poor sales growth of 5.49% over past five years.

    Compounded Sales Growth

    10 Years
    +3%
    5 Years
    +5%
    3 Years
    +6%
    TTM
    +12%

    Compounded Profit Growth

    10 Years
    +10%
    5 Years
    +15%
    3 Years
    +18%
    TTM
    +19%

    Stock Price CAGR

    10 Years
    +7%
    5 Years
    +10%
    3 Years
    +17%
    1 Year
    +5%

    Return on Equity

    10 Years
    +33%
    5 Years
    +48%
    3 Years
    +43%
    Last Year
    +46%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter75.00%75.00%75.00%75.00%0.00 pp
    FII4.63%4.62%4.79%4.75%-0.04 pp
    DII7.70%7.68%7.81%8.47%+0.66 pp
    Government0.00%0.00%0.00%0.00%0.00 pp
    Public12.67%12.69%12.42%11.77%-0.65 pp

    Filed with NSE for Sept 2026: promoters 75.00%, public 25.00%

    Analysts & fund holdings

    75%
    75% recommend buy
    4 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E39.0 vs 45.2
    Sector P/B6.05
    Beta0.61

    Who holds the shares, quarter by quarter

    Mutual funds 6.07% (+1.20 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters75.0%
    • Foreign institutions4.8%
    • Mutual funds6.1%
    • Insurance2.3%
    • Other domestic institutions0.1%
    • Retail9.5%
    • Others2.3%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    SBI Midcap Fund0.66%1.32%+0.01 pp
    Kotak Large & Mid Cap Fund0.61%0.89%-0.02 pp
    Nippon India Pharma Fund0.57%2.83%+0.17 pp
    Quant Mid Cap Fund0.49%2.97%+2.64 pp
    Nippon India Growth Mid Cap Fund0.32%0.29%-0.01 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    26.1%
    Downside volatility
    25.4%
    Worst 5% of days
    2.8%
    Average of that tail
    3.5%
    Max drawdown (1Y)
    26.6%
    Below its peak
    15.1%

    Against the market

    Beta vs Nifty 50
    0.46
    Correlation
    0.24
    Relative strength (3M)
    -6.3%
    ATR (14)
    3.1%

    Return

    Return 1M
    +2.8%
    Return 3M
    -2.4%
    Return 6M
    +10.4%
    Return 1Y
    +3.9%
    vs 200-day average
    +4.3%

    Momentum

    RSI (14)
    52.3
    MACD histogram
    23.09
    Stochastic %K
    54.7
    ADX (14)
    21.3
    +DI / −DI
    25.2 / 18.7
    Money flow index
    60.4

    Participation

    Delivery (20d avg)
    56.4%
    vs its 60-day baseline
    +4.5 pts
    Volume vs 20-day
    -0.1σ
    Close vs day's VWAP
    -0.8%
    52-week position
    53 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.

    Free cash flow
    ₹848 Cr
    FCF yield
    1.9%
    Cash conversion
    0.87
    Accruals ratio
    0.031
    Net debt
    -₹612 Cr
    Net debt / equity
    -0.33
    EV / sales
    10.60
    Capex intensity
    1.4%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹57.00

      Dividend - Rs 57 Per Share

      29 May 2026
      ex-date
    • dividend
      ₹42.00

      Dividend - Rs 42 Per Share

      30 May 2025
      ex-date
    • dividend
      ₹12.00

      Interim Dividend - Rs 12 Per Share

      7 Nov 2024
      ex-date
    • dividend
      ₹32.00

      Dividend - Rs 32 Per Share

      31 May 2024
      ex-date
    • dividend
      ₹32.00

      Dividend - Rs 32 Per Share

      30 Jun 2023
      ex-date
    • dividend
      ₹30.00

      Dividend - Rs 30 Per Share/Special Dividend- Rs 60 Per Share

      7 Jul 2022
      ex-date
    • dividend
      ₹30.00

      Annual General Meeting/Dividend - Rs 30 Per Share

      19 Jul 2021
      ex-date
    • dividend
      ₹20.00

      Dividend - Rs 20 And Special Dividend - Rs 20 Per Share

      17 Jul 2020
      ex-date
    • dividend
      ₹20.00

      Annual General Meeting/Dividend Rs 20 Per Share

      11 Jul 2019
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 1:1

      11 Sept 2018
      ex-date
    • dividend
      ₹35.00

      Dividend- Rs 35 Per Share

      13 Jul 2018
      ex-date
    • dividend
      ₹30.00

      Dividend - Rs 30/- Per Share

      14 Jul 2017
      ex-date
    • dividend
      ₹50.00

      Dividend Rs 50/- Per Share

      15 Jul 2016
      ex-date
    • dividend
      ₹62.00

      Annual General Meeting/Dividend - Rs 62..50/- Per Share

      23 Jul 2015
      ex-date
    • dividend
      ₹50.00

      Final Dividend Rs.50/- Per Share

      3 Apr 2014
      ex-date
    • dividend
      ₹50.00

      Dividend Rs. 50 Per Share

      4 Apr 2013
      ex-date
    • dividend
      ₹45.00

      Dividend Rs.45/- Per Share

      29 Mar 2012
      ex-date
    • dividend
      ₹40.00

      Dividend-Rs.40/- Per Share

      14 Mar 2011
      ex-date
    • dividend
      ₹30.00

      Dividend-Rs.30/- Pr Share

      10 Mar 2010
      ex-date
    • other
      Not available — not reported in this filing

      Div Fin-Rs.22 + Spl-Rs.18

      18 Mar 2009
      ex-date

    Company announcements

    Board MeetingPrice-sensitive
    Board Meeting Intimation for To Consider, Approve And Take On Record The Un-Audited Financial Results For The Second Quarter & Half Year Ended 30Th September 2026.

    Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve As per attachment

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    As per attachment

    Insider Trading / SAST
    Closure of Trading Window

    As per attachment

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    As per attachment

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

    Outcome of Postal Ballot

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    As per attachment

    AGM/EGM
    Corrigendum To The Notice Of Postal Ballot Dated August 3, 2026

    As per attachment

    Company Update
    Volume Movement Letter

    As per attachment

    Company UpdatePrice-sensitive
    Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd

    The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Ltd on August 26, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.

    Company Update
    Disclosure Under Regulation 30

    As per attachment

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    As per attachment

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    As per attachment

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Transcript

    Company Update
    Disclosure Under Regulation 30

    IT Refund of Rs 52 crores

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    As per attachment

    Filed with BSE (scrip 500660); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Open offer

      GlaxoSmithkline Pharmaceuticals Limited

      26 Dec 2013
      Read on SEBI

    Documents

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Glaxosmithkline Pharmaceuticals: common questions

    Answered from the figures on this page.

    Glaxosmithkline Pharmaceuticals last traded at ₹2,638.20 (NSE, as of 18 Nov 2026). The last session moved it down 1.84%.

    Glaxosmithkline Pharmaceuticals is valued at about ₹44,693 crore (NSE, as of 18 Nov 2026).

    Glaxosmithkline Pharmaceuticals trades at a price-to-earnings ratio of 38.98 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Glaxosmithkline Pharmaceuticals has traded between ₹2,088.10 and ₹3,120.70 over the past 52 weeks, to 18 Nov 2026. It is currently 53% of the way up that range.

    Glaxosmithkline Pharmaceuticals (GLAXO) is classified under Pharma on this site's screener.